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Summary 
 
Parkinson’s disease (PD) is characterized by the 
progressive death of dopaminergic neurons in the 
human brain. The misfolding and aggregation of α-
synuclein, as well as the presence of reactive 
oxygen species (ROS), are thought to contribute to 
this cytoxicity. The mechanism of interaction 
between these two pathways is unknown. 
Mitochondrial dysfunction, specifically, incomplete 
respiratory metabolism and loss of antioxidants, 
has long been implicated as the culprit for ROS 
accumulation. Our lab has previously developed 
budding and fission yeast models to study genetic 
regulation of α-synuclein misfolding and toxicity. 
My thesis is composed of two studies. For my first 
goal, I tested the hypothesis that a mitochondrial 
dysfunction would enhance α-synuclein misfolding, 
aggregation, and toxicity. I used two budding 
yeasts strains, one knocked-out for α-ketoglutarate 
dehydrogenase (the respiratory mutant) and 
mitochondrial glyoxalase II (the anti-oxidant 
mutant) to study the combinatorial effects of 
oxidative stress and expression of human α-
synuclein. We found no cellular toxicity and 
decreased α-synuclein expression in both strains, 
yet intracellular aggregates only in the respiratory 
mutant. For my second goal, I tested the hypothesis 
that changing key amino acids within α-synuclein 
would affect its folding and toxic properties. 
Specifically, I investigated a mathematically 
modeled mutation of α-synuclein, Ala76→Glu, which 
is thought to change its shape in a way that 
decreases its rate of aggregation. In fission yeast, 
A76E-α-synuclein formed aggregates more slowly 
than the normal form and did not change toxicity or 
expression. In budding yeast, A76E-α-synuclein 
reached the membrane more slowly, initially had 
decreased expression, and exhibited no toxicity. 
Results from these two studies assert that 
mitochondrial dysfunction and α-synuclein shapes 
play a role in the manifestation of Parkinson’s 
disease.  
 
Introduction 
 
Neurodegeneration is characterized by the progressive 
death of neurons in the central nervous system leading 
to an array of dementias and motor dysfunctions. The 
past decade has witnessed rapid convergence in the 
study of neurodegenerative diseases (NDD; Figure 1). 
Scientists immersed in the evaluation of Alzheimer’s 
disease (AD), Huntington’s disease, transmissible 
spongiform encephalopathies, Parkinson’s 
disease(PD),  and many other NDD are coming 
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together and finding common disease-causing 
pathways (Muchowski 2002). As a result, scientists 
studying NDD are asking the same questions about 
their respective discipline. Their questions are so 
similar that they can be applied to virtually any NDD 
model. Moreover, within each NDD, seemingly 
unrelated disease-causing pathways are being linked 
together.   
Principally, neurodegeneration is 
pathologically highlighted by proteinaceous deposits in 
and around dying neurons. To that end, key proteins 
have been identified as culprits for each NDD. Familial 
forms of NDD generally come from a mutation in that 
protein. However, most NDD are recorded as sporadic 
events where the protein acquires a different shape due 
to a mutation, post-translational modification, inactivity 
of a chaperone, or even the interaction with an 
infectious protein (i.e. prions; Ellis et. al., 2002). For 
instance, in Alzheimer’s disease, Aß amyloid is found in 
extracellular aggregates (Caughey et. al., 2003). 
Consequently, this key protein typically attains an anti-
parallel ß-sheet conformation, which ultimately self-
assembles to form fibrils and then aggregates—a 
common pathological feature among NDD. Scientists 
have yet to discover whether or not insoluble protein 
aggregates are neuroprotective or cytotoxic. Some now 
argue that the soluble pre-fibrillar intermediates—
protofibrils—are the key toxic microelements (Caughey 
et. al., 2003). Furthermore, intense research is 
attempting to unravel the toxic elements in NDD, which 
is being progressively combined with pathways in 
mitochondrial dysfunction and oxidative stress in NDD.  
Aging, and its deleterious effects on the 
organism, is partly due to the cell’s inability to regulate 
its redox status. Accumulating evidence suggests that 
mitochondrial dysfunction and oxidative stress are key 
factors in the onset and development of NDD (Dauer et. 
al., 2003).  Oxidative stress is the accumulation of 
reactive oxygen species (ROS), which has been 
recently evaluated as a unifying factor in PD 
pathogenesis (Abou-Sleiman et.al., 2006). Non-dividing 
neurons in the human brain are especially sensitive to 
oxidative stress because their longevity allows for the 
progressive buildup of oxidatively modified DNA, 
proteins, and lipids.  
The aggregation of misfolded proteins and 
mitochondrial dysfunction are not mutually exclusive. 
Research has only recently been able to make ties 
between each respective theory as a result of genetic 
screens (Clark et.al., 2006). By studying the cellular 
events that cause PD, we may be able to elucidate the 
mechanism by which proteins misfold in all NDD.  
Unfortunately, the toxic molecules 
responsible for PD still remain to be resolved (Dauer et. 
al., 2003). α-Synuclein, the protein that misfolds in PD, 
forms aggregates that may be toxic or protective to the 
cell (Caughey et. al., 2003). Combined with 
accumulating ROS, the disease-causing agent remains 
to be determined. My thesis is divided into two studies 
which involves the understanding of two questions. 
How does mitochondrial dysfunction contribute to α-
synuclein misfolding and toxicity? And, how does  
  
 
Figure 1. Protein Misfolding is a Common Theme in 
Neurodegenerative Diseases. All progressively fatal 
neurodegenerative diseases are associated with the misfolding 
of a key protein. The aggregation of these proteins is 
hypothesized to cause cell death in the brains of patients with 
the above diseases. Due to their mechanistic unity, the 
elucidation of one disease pathway may allow for the 
understanding of the others. The dotted line indicates a 
correlation and not a linear causal relationship.  
 
altering the shape of α-synuclein contribute to its rate of 
aggregation and toxicity?  
The following subsections will highlight the mechanisms 
behind mitochondrial dysfunction and α-synuclein 
aggregation in PD. I will then provide my thesis 
hypotheses, aims, and experimental design. 
 
Parkinson’s Disease 
Nearly 500,000 people are afflicted with PD in the 
United States, making it the second most prevalent 
neurodegenerative disease after AD (Caughey et. al., 
2003). Neuronal death in PD specifically occurs in 
dopaminergic neurons of the substantia nigra pars 
compacta (SNpc). The progressive developement of 
cytoplasmic inclusions, known as “Lewy bodies” (LB), in 
the SNpc is correlated with cell death (Spillantini et. al., 
1998). LB are predominantly composed of α-synuclein, 
a cytosolic protein of unknown function. Additionally, 
extensive neurodegeneration and LB presence is 
observed in non-dopaminergic systems in PD: locus 
coeruleus, raphe, cerebral cortex, and olfactory bulbs 
(Dauer et. al., 2003).   
Patients with PD generally experience 
postural rigidity, resting tremors, and slowness of 
movement (Goedert et. al., 2001). Clinical 
manifestations of PD are due to striatal scarcities in 
dopamine, which can be abated by replenishing 
dopamine concentrations with the precursor levodopa 
(L-3,4-dihydroxyphenylalanine; Dauer et. al., 2003). 
Interestingly, positron emission tomography (PET) 
imaging can be used to measure dopamine synthesis 
and transport to detect presymptomatic stages of the 
disease (Elsinga et. al., 2006). The development of 
PET detection of PD has reemphasized the utility of PD 
vaccination with α-synuclein antibodies—currently in 
clinical trials (Pilcher 2005)—before symptoms arise in 
diagnosed patients (May et. al., 2006). A step toward α-
synuclein toxicity is its localization to the plasma 
membrane of substantia nigral cells (Masliah et. al., 
2005). Thus, α-synuclein antibodies have been 
implicated as a promising preventative treatment due to 
the antibodies’ ability to neutralize toxic α-synuclein  
bound to the outside membrane.   
Parkinson’s disease is 95% idiopathic; yet, 
accumulating evidence suggests familial and 
environmental links to PD. New familial links to PD are 
α-synuclein-centric autosomal-dominant mutations 
(Hofer et. al., 2004).  In 1997, Contursi and colleagues 
reported an A53T missense mutation in the α-synuclein 
gene of a Greek family. The following year, an A30P 
mutation was coupled with early-onset PD in a German 
family (Krueger et. al., 2001). Then in 2004, a Spanish 
family was found to have an E46K mutation, within a 
conserved region of α-synuclein, which displayed 
classical PD pathology with Lewy body dementia 
(Zarranz et. al., 2004). These developments 
demonstrate a genetic connection to PD. Newly 
discovered autosomal-recessive genes, with the 
exception of LRRK2 which is autosomal-dominant 
(Paisan-Ruiz et al., 2004; Zimprich et al., 2004), have 
been identified and intimately tied to α-synuclein-
dependent toxicity: UCH-L1 (Funayama et al., 2002), 
Parkin (Kitada et al., 1998), DJ-1 (Bonifati et al., 2003), 
and PINK1 (Valente et al., 2004). These autosomal-
recessive genes, when deficient, cause PD without LB 
pathology.    
 
Pharmacological Evidence for Mitochondrial 
Dysfunction in Parkinson’s Disease 
Not only can PD be caused by familial mutations, but 
chemical agents can be used to create PD-like 
symptoms. An environmental toxin based model of PD 
established itself in 1983 by Langston and colleagues. 
The environmental toxin 1-methyl-4-phenyl-1,2,5,6-
tetrahydropyridine (MPTP) caused acute and 
irreversible damage to the SNpc without LB. MPTP-
dependent parkinsonism was challenged with levodopa 
treatment, which equivalently rescued symptoms when 
compared to PD patients. Other recently discovered 
environmental toxins, such as paraquat and rotenone 
cause less acute dopaminergic degeneration but form 
α-synuclein dominant LB structures (Dauer et. al., 
2003). Consequently, all three toxins inhibit 
mitochondrial complex I activity, which generates rapid 
generation of ROS, decreased ATP production, and 
increased intracellular calcium, thereby causing 
excitotoxic-related cell damage (Abou-Sleiman et. al., 
2006). Therefore, the ongoing investigation of PD 
pathogenesis has uncovered two distinct pathways, but 
only loose relationships between them (Figure 2).  
 
Genetic Evidence for Mitochondrial Dysfunction in 
Parkinson’s Disease 
Pedigrees of families with PD have given scientists 
unique insight into its genetic basis. Among the newly 
discovered autosomal-recessive Parkinson’s disease-
linked genes, PINK1 and parkin give us a way to link 
mitochondrial dysfunction with the ubiquitin proteasome 
system, thus combining two disparate disease-causing 
pathways into one schematic (Figure 2; Park et. al., 
2006; Clark et. al., 2006; Yang et. al., 2006; Wang et. 
al., 2006).  
The parkin gene has been implicated in a 
form of recessive parkinsonism. Ironically, its  
  
 
Figure 2. The Role of α-Synuclein and Mitochondrial Dysfunction in Parkinson’s Disease. Sporadic, genetic, and environmental 
factors lead to Parkinson’s disease pathogenesis. Emerging evidence suggests that these three factors can interact and synergistically 
affect α-synuclein folding. The pathways illustrated above shows α-synuclein at the center. Yet, environmental toxins, such as MPTP, lead 
to dopaminergic degeneration without Lewy body inclusions or α-synuclein-rich aggregates. The dotted pathways indicate that the main 
toxic agent, either protofibrils or Lewy bodies, remains to be determined (Conway et. al., 2001).    
 
 
phenotype is devoid of LB, pathology similar to MPTP 
exposure (Cookson et. al., 2005). This suggests that LB 
are not needed for PD to occur. Parkin codes for a 
ligase that tags damaged or misfolded proteins with 
ubiquitin (Cookson et. al., 2005). The tagged proteins 
are then recycled in the proteasome. PINK1 is 
structurally and functionally different from parkin, but is 
also implicated in a recessive form of PD. It encodes a 
kinase that localizes to the intermembrane space of 
mitochondria (Abeliovich et. al., 2006). Yet, the 
question remains, how do these different proteins 
contribute to our understanding of PD? 
 Park et. al. (2006) and Clark et. al. (2006) 
have shown that knock-out mutants for parkin and 
PINK1 are the key to understanding their purpose in PD 
pathogenesis. When PINK1 was removed from the flies 
(i.e. Drosophila melanogaster), dopaminergic 
degeneration with motor defects were observed (Park 
et. al.  2006). Thus, a dysfunctional mitochondria, due 
to PINK1 deletion, created a parkinsonian phenotype in 
flies. Interestingly, the PINK1 mutant phenotype was 
found to be nearly identical to the parkin mutant (Park 
et. al., 2006). This similarity between both fly strains 
generated curiosity about how these two proteins may 
interact.   
In a novel experiment, Park and colleagues 
(2006) overexpressed parkin in a PINK1 mutant. 
Suprisingly, energy production was recovered. They 
concluded that parkin is protective against 
mitochondrial dysfunction. Inversely, PINK1 
overexpression in a parkin mutant showed no rescue 
effect. Therefore, Park et. al. (2006) along with Clark et. 
al. (2006) and Yang et. al. (2006) concluded that parkin 
functions downstream of PINK1—a single linear 
pathway between the mitochondria and ubiquitin 
proteasome system.  
These insights into the biology of Parkinson’s 
disease have intimately tied mitochondrial dysfunction 
and the UPS in a programmed cell-death model of PD. 
Mitochondrial dysfunction can be induced in other ways 
to generate PD-like pathology. 
 
Cell Death Modulators in the Midbrain   
Oxidative stress may play a role in substantia nigra 
specific atrophy (Lin et. al., 2006). Oxidative 
modifications significantly change α-synuclein and 
dopamine function, which are then found to increase 
sensitivity of SNpc neuronal degeneration (Galvin et. 
al., 2006). Neuromelanin, with its high iron content, 
which pigments the SNpc, may provide a necessary 
oxidative stress mechanism to specifically destroy the 
SNpc (Zecca et al., 2006).  Iron may aggressively 
catalyze ROS generation from oxygen-containing 
substrates like hydrogen peroxide (Gerlach et. al., 
2003; Figure 3). Additionally, mitochondrial dysfunction 
by inhibition of complex I may act as possible conduit 
for a mitochondrial-dependent apoptotic pathway 
(Tatton et. al., 2003). Thus, the disparate pathways of 
cell death, due to oxidative stress, emphasize further 
understanding of SNpc specific degeneration.  
 Dopamine auto-oxidation has long been an 
attractive hypothesis for SNpc selective death due to its 
endogenous metabolism in the SNpc (Graham 1978). 
Normal metabolism of dopamine produces hydrogen 
peroxide and superoxide radicals, which oxidize 
dopamine to form dopamine ortho-quinone (Dauer et. 
al., 2003), similar in structure to rotenone, a complex I 
inhbitor and ROS generator. Dopamine ortho-quinone 
  
Figure 3. Dopamine Neurons are Specifically Sensitive to ROS. The specific death of substantia nigra neurons in PD is due to toxic 
relationships between α-synuclein, dopamine, iron-neuromelanin complexes, and ROS. Oxygen radicals can form in two ways: one, 
hydrogen peroxide and ferrous iron produce a hydroxyl radical and anion, as well as, ferric iron by the Fention reaciton; two, inhibition of 
complex I in the mitochondria induces singlet oxygen radical production. Dopamine can also become oxidized which can then inhibit the 
dopamine reuptake transporter and stabilize toxic protofibril aggregate intermediates. Thus, accumulation and generation of oxygen 
radicals in the substatia nigra is a self-perpetuating process, due to the physical properties of these neurons. 
 
then proceeds to disrupt all proteins with disulfide 
linkages (Dauer et. al., 2003). Auto-oxidation thus has a 
four-fold effect on the cell (Figure 3). One, the 
disassembly of proteins with disulfide linkages places 
an unnecessary stress and load on the ubiquitin-
proteasome protein degradation system (UPS; Dauer 
et. al., 2003). Two, ROS generated by dopamine 
metabolism increases general protein misfolding in the  
cell, thus further increasing the load onto the UPS. 
Three, dopamine ortho-quinone, like rotenone, may 
inhibit mitochondrial complex I activity. And four, 
dopamine ortho-quinone can inhibit the dopamine 
transporter on the pre-synaptic bouton, which allows 
dopamine to stay in the synapse and over activate the 
post-synaptic membrane, thus having similar effects as 
cocaine (Whitehead et. al., 2003). All of these 
constituents of dopamine metabolism prime SNpc 
neurons for self-destruction. Thus, programmed cell-
death, induced by ROS and mitochondrial dysfunction, 
may lead to specific death of SNpc neurons. 
 
α-Ketoglutarate Dehydrogenase Model for PD 
With the advent of MPTP studies, the respiratory chain 
in the mitochondria has been long considered as a 
major site of ROS generation. Specifically, inhibition of 
complex I, NADH ubiquinone oxidoreductase, is a 
plausible site of ROS production due to its sensitivity to 
oxidative stress; only 25-30% inhibition of complex I is 
necessary to induce parkinsonism (Adam-Vizi 2005). 
Yet, there are other factors that contribute to the toxic 
redox status in SNpc neurons.   
 Decreased activity of α-ketoglutarate 
dyhydrogenase (α-KGDH), a regulatory Kreb’s cycle 
enzyme, disrupts the redox status in brains of 
Parkinson’s and Alzheimer’s disease patients (Gibson 
et. al., 2000). To gauge its effect, mitochondrial 
membrane potentiation is used as an indicator of 
oxidation-reduction reactions taking place within the cell 
(Gibson et. al., 2000). Loss of membrane potentiation 
leads to an apoptotic state within the cell, as described 
above. α-KGDH is regulated by the NADH/NAD+ ratio, 
Ca2+, and ADP (Adam-Vizi, 2005). Its loss-of-function 
would thus eliminate a key modulating location in 
glucose metabolism. Interestingly, the isolated enzyme 
produces hydrogen peroxide and superoxide radicals in 
vitro (Tretter and Adam-Vizi, 2004). These results were 
found to hold true in vivo as well (Starkov et. al., 2004). 
This generation of ROS was dependent on the 
NADH/NAD+ ratio, where increasing NADH levels 
account for this phenomenon. Increasing ROS levels 
actually inhibit α-KGDH (Tretter and Adam-Vizi, 1999). 
The inhibition of α-KGDH reduces NADH for the 
  
electron transport chain, thus decreasing ATP 
production. Thus, by these inverse pathways, α-KGDH 
is both a target and generator of oxidative stress.   
 Markedly, α-KGDH may regulate complex I 
activity by these inverse pathways (Adam-Vizi, 2005). 
As stated before, inhibition of α-KGDH reduces NADH 
production which kinetically decreases complex I 
(NADH ubiquinone oxidoreductase) activity. The other 
inhibitory pathway is set in motion by a high NADH 
concentration. Thus, complex I is kinetically active 
under these conditions. The generation of ROS by α-
KGDH in the mitochondrial matrix may disrupt complex 
I activity (Figure 4). Also, the ROS generated by α-
KGDH would increase lipid peroxidation thereby 
disrupting calcium homeostasis. Lipid disruption would 
furthermore perturb the pH gradient across the inner 
membrane space. The loss of membrane potentiation is 
a step towards apoptosis. Loss of α-KGDH activity and 
inhibition of complex I is a similar to the MPTP-based 
model of PD. 
Loss of α-KGDH activity also occurs in AD. 
Gibson and colleagues (1988) have demonstrated that 
α-KGDH activity is reduced by 40-75% in AD brains. 
Reduction in α-KGDH levels is negatively correlated 
with neurofibrillary tau tangle counts, suggesting this 
enzyme is involved in the neurodegenerative cascade. 
Even 10 to 15% reduction in available glucose or 
oxygen can reduce brain function, including decline in 
memory (Gibson et. al., 2005). A current study shows 
how brain regions with low metabolic activity 
accumulate more plaques in conjunction with dementia 
(Shoghi-Jadid et. al., 2002). The return of glucose to 
these brain regions reverses some behavioral deficits of 
AD. This suggests that symptoms in AD are not always 
attributed to neurodegeneration.   
 
Mitochondrial Glyoxalase II and Neurodegeneration 
The maintenance of antioxidants within a cell is the 
responsibility of a network of proteins, such as 
catalases, superoxide dismutases, reductases, and 
peroxidases (Lin et. al., 2006). A not so common 
constituent of this network is the glyoxalase system 
(Bito et. al., 1997). This system is present within many 
organisms and is thought to be ubiquitous (Bito et. al., 
1997). The main function of glyoxalases is to detoxify a 
by-product of glucose metabolism, methylglyoxal (2-
oxoaldehyde). The coordination of glyoxalase I and II 
allow for the complete conversion of this toxic molecule 
to D-lactate and glutathione (Bito et. al., 1999). 
Glutathione is a major redox molecule and antioxidant 
which sequesters and inactivates ROS (Drechsel et. al., 
2007). Thus, the glyoxalase system is both an 
antioxidant system, because it detoxifies aldehydes, 
and a generator of antioxidants, glutathione.   
The function of the glyoxalase system has 
been implicated in neurodegenerative diseases. In PD 
and AD, Lewy Bodies and neurofibrillary tangles are 
oxidatively modified, resulting in toxic advanced 
glycation end products (Webster et. al., 2005). Among 
the many reactive carbonyls, methylglyoxal is thought 
to be the primary substrate for this conversion (Webster 
et. al., 2005). The accumulation of methylglyoxal is 
correlated with mitochondrial deficiencies and even 
apoptosis (Xu et. al., 2006). A dysfunctional glyoxalase 
system would have a two-fold deleterious effect. One, 
methylglyoxal would be more available to oxidatively 
modify other proteins. Two, the production of 
glutathione would be inhibited, thus oxidants would 
have a higher chance of accumulating and damaging 
cellular structures.   
For my first thesis goal, I evaluated the role of 
mitochondrial dysfunction in PD using a respiratory (α-
ketoglutarate dehydrogenase) and antioxidant mutant 
(mitochondrial glyoxalase II) to study the aggregation 
and toxicity of α-synuclein. 
 
 α-Synuclein’s Biological and Pathogenic Properties   
The concept of mutant α-synuclein sharing pathogenic 
pathways with sporadic PD is largely based on α-
synuclein-rich LB (Dauer et. al., 2003). Yet, the exact 
cellular function of α-synuclein is unknown. 
α-Synuclein is a small, 140 amino acid, 14 
kDa, natively unfolded protein found in presynaptic end 
terminals throughout the entire central nervous 
system—not just in the SNpc—alongside synaptic 
vesicles (Kahle et. al., 2002). The endogenous location 
of α-synuclein plays a role in learning, memory, and 
synaptic plasticity within songbirds (Clayton et. al., 
1999). α-Synuclein regulates vesicular-trafficking, which 
may suggest it’s role in synaptic plasticity (Jensen et. 
al., 1998). Furthermore, α-synuclein is found lacking a 
native secondary structure in the cytosol (Weinreb et. 
al., 1996). Strikingly, small acidic lipid vesicles are 
found attached with an 80% helical-α-synuclein 
structure (Davidson et. al., 1998). α-Synuclein loses its 
normal function upon lipid binding; this may play a role 
in neuronal death in PD. The sequestered α-synuclein 
would seemingly not play an active role in synaptic 
plasticity, possibly leading to repressed vesicle release. 
This in turn may cause synaptic connections to degrade 
due to diminished communication between neurons.  
Although α-synuclein’s normal function is 
unknown, properties that allow and protect it from self-
assembly have recently been investigated. α-Synuclein 
is characterized in three sections: N-terminal, central, 
and C-terminal domains. Interestingly, 11-amino acid 
variable repeats, XKTKEGVXXXX, exist mainly on the 
N-terminus (7 conserved repeats), but also on the C-  
 
 
 
Figure 4. α-KGDH Regulation of Complex I Activity by ROS 
and NADH Levels. Evidence for the above pathways is 
adapted from Tretter et. al. (2004; 2005). The two red 
perpendicular lines indicate inhibition.   
A. ROS Inhibition of α-KGDH. ROS inhibits α-KGDH which 
decreases the production of NADH in the Kreb’s cycle. The lack 
of NADH lowers complex I activity, thus ATP is not synthesized.  
B. ROS Generation by α-KGDH. A high concentration of NADH 
increases the activity of both α-KGDH and complex I. Yet, this 
dual activation is counterintuitive. α-KGDH produces ROS when 
NADH levels are high. This may, in turn, inhibit previously 
activated complex I. 
  
terminus (only 2; Kessler et al., 2003; Uversky et al., 
2002). These regions are found to inhibit the toxic 
conversion to a β-sheet-rich conformation and thus 
prevent fibrillization and aggregation. Yet, familial 
mutations, have been found to increase the rate of 
fibrillization, A30P slower than A53T (Conway et. al. 
1998). This suggests that a mutation may induce β-
sheet sheet conversion from an unfolded or α-helical 
state. Soon after, an α-synuclein fibril intermediate was 
discovered by Conway and colleagues (2001) with 
atomic force microscopy and hypothesized to be the 
causative agent in PD. The intermediate was coined the 
protofibril, which can bind and permeabilize lipid 
membranes, thereby destroying the integrity of the cell. 
Whether or not protofibrils or aggregates cause cell-
death in PD is still controversial.   Shape changes may 
also affect lipid binding properties of α-synuclein. The 
binding affinities of A30P and A53T α-synuclein to lipids 
have been studied previously in our lab (Sharma et. al., 
2006). Interestingly, E46K and A53T preferentially 
bound lipids when compared to A30P. A shape change 
to an α-helical conformation accounts for the enhanced 
membrane-binding in a synthetic model (Davidson et. 
al., 1998). Further analysis suggests that the C-
terminus binds to the membrane, where the N-terminus 
is unbound (Eliezer et. al., 2001).  
The variable shape of α-synuclein may 
account for its acquisition of toxic properties or lack 
thereof. Chiti and colleagues (2003), mathematically 
modeled protein aggregation rates as a function of 
three physicochemical parameters: hydrophobicity, 
tendency to convert from α-helical to β-sheet 
conformation, and charge. They suggested that either 
an A76E or A76R α-synuclein would inhibit aggregation 
and thus not cause disease. Since most proteins have 
not been evolutionarily optimized to resist aggregation, 
the modeled amino acid substitutions may delay the 
self-assembly of α-synuclein, an aggregation-prone 
protein (Caughey et. al., 2003).  Thus, for my second 
thesis goal, I evaluated the aggregation and toxicity of 
A76E-α-synuclein and its ability to reduce the rate of 
fibril formation.   
 
Yeast Model for PD 
Our lab has developed budding and fission yeast 
models of PD to study the genetic regulation of human 
α-synuclein misfolding and toxicity. Saccharomyces 
cerevisiae (budding yeast) is a powerful genetic system 
to model protein misfolding processes underlying 
human diseases (Outeiro and Muchowski, 2004), 
including prion disease (Ma and Lindquist, 1999), 
Huntington’s disease (Krobitsch and Lindquist, 2000; 
Muchowski et al., 2000) and amyotrophic lateral 
sclerosis (Kunst et al., 1997). Recently, three S. 
cerevisiae models for α-synuclein have shed new 
insight into α-synuclein’s pathology and biology 
(Outeiro and Lindquist, 2003; Dixon et al., 2005; 
Zabrocki et al., 2005). Additionally, a yeast genetic 
screen revealed 86 genes that were synthetically lethal 
with overexpressed α-synuclein (Willingham et al., 
2003). 
Schizosaccharomyces pombe (fission yeast) 
is also a powerful model organism in cell biology, 
providing insight into the eukaryotic cell cycle (Fantes 
and Beggs, 2000), DNA repair and recombination 
(Davis and Smith, 2001), and checkpoint controls 
needed for stability (Humphrey, 2000). Like budding 
yeast, fission yeast shares with humans a high 
conservation of protein folding and protein quality 
control pathways (Wood et al., 2002).  
 Previous findings in our lab have evaluated 
the misfolding, aggregation, and toxicity of WT-α-
synuclein and three mutants (A30P, A53T, A30P/A53T) 
in budding yeast when regulated by oxidative stress 
and proteasomal deficiencies (Sharma et. al., 2006). 
Prominent localization of WT and A53T α-synuclein 
was found near the plasma membrane. Contrastingly, 
A30P displayed cytoplasmically diffuse localization 
compared to a mixed phenotype from A30P/A53T. 
Within the strains tested, α-synuclein did not contribute 
to cellular toxicity. In a proteasomal barrel mutant 
(doa3-1), production of α-synuclein was delayed, where 
in a proteasomal cap mutant (sen3-1) α-synuclein 
aggregation was observed. When cells lacking 
manganese superoxide dismutase (sod2) where 
challenged with hydrogen peroxide, α-synuclein was 
extremely lethal. This toxicity was not seen in a copper, 
zinc superoxide dismutase (sod1). No aggregates were 
seen in sod2∆ cells despite the lethality. These 
experiments support the oligomeric hypothesis as the 
primary toxic species in PD.  
In second study, we used fission yeast to 
study a different property of α-synuclein misfolding and 
aggregation (Brandis et. al., 2006). Wild-type α-
synuclein and three mutants (A30P, A53T, and 
A30P/A53T) were expressed with vectors of increasing 
promoter strength to directly test in living cells the 
nucleation polymerization hypothesis for α-synuclein 
misfolding and aggregation. In support, A53T formed 
aggregates in a time- and concentration-dependent 
manner. Cells expressing A30P/A53T did not exhibit 
this quality due to cytoplasmic localization of α-
synuclein. Wild-type α-synuclein formed aggregates at 
a slower rate than A53T. Suprisingly, A53T did not 
localize to the membrane, even at low concentrations 
allowing for intermediate fibrillization. Toxicity was not 
observed in all cases tested. Thus, we speculate 
toxicity is linked to membrane binding capacity.   
Budding and fission yeast model different, yet 
similar properties of α-synuclein pathobiology.  For my 
thesis, I have conducted two studies using both yeasts 
to understand two separate questions. One, how does 
mitochondrial dysfunction play a role in PD? Two, can a 
mutation in α-synuclein change its rate of aggregation?  
 
Study One: Mitochondrial Mutants  
Hypothesis: Mitochondrial dysfunction will enhance α-
synuclein misfolding, aggregation, and toxicity. 
My aim was to evaluate two non-essential 
mitochondrial budding yeast knockout strains to 
understand the effect of mitochondrial deficiencies on 
α-synuclein misfolding and toxicity. Previous studies in 
our lab suggest that the mitochondria is implicated in α-
synuclein toxicity and gave precedence for my 
evaluation (Sharma et. al., 2006). Among the 
enhancers studied by Willingham and colleagues 
(2003) I investigated orthologs for α-ketoglutarate 
dehydrogenase (kgd1p) and mitochondrial glyoxalase II 
(glo4p), which were knocked-out and found to be 
sensitive to α-synuclein-induced toxicity. To test this 
hypothesis, I expressed wild-type and three mutant 
forms of human α-synuclein tagged in the kgd1∆ and 
glo4∆ yeast strains. Data gathered from these 
experiments was compared to their isogenic parent 
strain, BY4741, without the specified gene deletions. 
Additionally, the localization and expression of α-
synuclein was evaluated to determine the effects of α-
synuclein concentration and position in accordance with 
cell viability. This analysis allowed us to further 
characterize which α-synuclein isoform and/or 
  
aggregate intermediate is responsible for cellular 
toxicity when paired with mitochondrial dysfunction.  
 
Study Two: The A76E α-Synuclein Mutation 
Hypothesis: The A76E α-synuclein mutation will 
decrease its rate of aggregation and delay membrane 
localization.  
 My aim was to create the A76E α-synuclein 
mutation and test its localization properties in both 
budding and fission yeast. In budding yeast, I predicted 
that A76E α-synuclein would decrease its affinity to 
bind membranes and cause toxicity through a soluble 
aggregate intermediate (Figure 5A and 5B). In fission 
yeast, I predicted that A76E α-synuclein would reduce 
its aggregation and cause toxicity (Figure 5C and 5D).  
To test this hypothesis, I compared A76E-α-
synuclein-expressing cells with WT-α-synuclein-
expressing cells in BY4741 (budding yeast) and TCP1 
(fission yeast) Here, I monitored the fluorescence 
patterns, toxicity, and expression α-synuclein tagged to 
GFP. This investigation will aid in our understanding of 
in vivo aggregation kinetics in the pathogenic α-
synuclein protein.  
 
Chapter 1: Mitochondrial Mutants Change α-Synuclein 
Folding and Aggregation 
 
Materials and Methods 
 
Methods adapted from Sharma et. al., (2006). 
 
α-Synuclein Expression Vector Constructs.  
The pYES2.1/V5-His-TOPO yeast expression vector 
(Invitrogen) was used for all α-synuclein expression in 
budding yeast. The following five vector constructs 
were previously created for each experiment: green 
fluorescent protein (GFP), wild-type α-synuclein, A30P, 
A53T, and E46K isoforms of α-synuclein. These 
mutants were also tagged at the C-terminus with GFP. 
For all experiments the pYES2.1/V5-His-TOPO vector 
and the GFP tagged vector were used as expression 
controls (See Table 1 for List of Constructs)  
 
Yeast Strains. 
The parent budding yeast (Saccharomyces cerevisiae) 
strain, BY4741 (MATa his3∆1 leu2∆0 met15∆0 ura3∆0) 
was purchased from Open Biosystems (Huntsville, AL). 
A respiratory deficient BY4741strain, knocked out for 
alpha-ketoglutarate dehydrogenase (kgd1∆) and 
glutathione deficient strain, knocked out for 
mitochondrial glyoxalase II (glo4∆) was also bought 
from Open Biosystems.  
 
Yeast Expression. 
Expression vectors, containing the ura3 gene, were 
transformed into yeast as described in Burke and 
colleagues (2000). Yeast cells were grown on synthetic-
complete media devoid of uracil (SC-URA) to select for 
transformed cells. Plasmid presence was verified by 
fluorescence microscopy and polymerase-chain 
reaction (PCR). A galactose inducible promoter (GAL1), 
coupled to the pYES2.1 vector, allowed for the 
regulation of α-synuclein expression. Yeast were first 
grown overnight in 5 mL of 2% SC-URA glucose media 
for 12 hours in a shaking-incubator at 30°C. Cells were 
then diluted to a concentration of 5 x 106 cells/ml and 
transferred into 2% SC-URA galactose media for 
induction of GFP and α-synuclein expression. Cell 
concentration was obtained by counting using a 
hemocytometer.  
Western Analysis. 
A concentration of 2.5x107 yeast cells/ml were washed 
in 50 mM Tris (pH 7.5), 10 mM NaN3 and solubilized in 
Electrophoresis Sample Buffer (ESB; Burke, 2000) 
containing 2% sodium dodecyl sulfate (SDS), 80 mM 
Tris (pH 6.8), 10% glycerol, 1.5% dithiothreitol, 1 mg/ml 
bromophenol blue, and a cocktail of protease inhibitors 
and solubilizing agents (1% Triton-X 100, 1 mM 
phenylmethylsulfonyl fluoride, 1 mM benzamidine, 1 
mM sodium orthovanadate, 0.7 µg/ml pepstatin A, 0.5 
µg/ml leupeptin, 10 µg/ml E64, 2µg/ml aprotinin, and 2 
µg/ml chymostatin). Samples were loaded onto 10-20% 
Tris-Glycine gels (Invitrogen) using Tris-Glycine-SDS 
running buffer (pH 8.3). Gels were transferred onto 
PVDF membranes and immunodetection was done with 
anti-V5 AP monoclonal antibody using standard 
protocols and detected for alkaline phosphatase activity 
(NBT/BCIP). A loading control was measured with an 
anti-PGK monoclonal antibody.  
 
Growth Curve Analysis.  
Flasks with 25 ml SC-URA galactose were each 
inoculated to 2.0x106cells/ml density after overnight 
growth in SC-URA glucose at 30°C . At 0, 6, 12, 18, 24, 
36, and 48 hours, duplicate measurements were taken 
from each sample. One ml of cell culture was pipetted 
into a cuvet to measure absorbance at 600 nm using a 
Hitachi U-2000 Spectrophotometer. Spectroscopic 
growth analysis was performed at least three times for 
each yeast strain.  
 
 
 
Figure 5. Hypothesis for A76E-α-Synuclein Localization in 
Budding and Fission Yeast. A. WT-α-Synuclein-GFP in  S. 
cerevisiae. WT-α-synuclein localizes to the plasma membrane 
in budding yeast at 24 hours of induction. B. A76E-α-Synuclein-
GFP in S. pombe. I hypothesized that A76E-α-synuclein will 
delay membrane localization and remain cytoplasmically diffuse 
at 24 hours of induction. C. WT-α-Synuclein-GFP in  S. pombe. 
Expression of WT-α-synuclein in fission yeast produces 
aggregates at 24 hours of expression. D. A76E-α-Synuclein-
GFP in S. pombe. I hypothesized that A76E-α-synuclein 
expression in fission yeast will delay aggregation at 24 hours of 
induction.  
  
 
 
Table 1. List of Transformed Budding Yeast Strains for Chapter 1 
 
 
Spotting Growth Analysis. 
Cells were grown for 12 hours in SC-URA glucose at 
30°C and adjusted to equal concentrations (2x107 
cells/ml), serially diluted (five-fold) into 96-well 
microwell plates and spotted on SC-URA glucose (2%)  
and galactose (2%) plates using a 48-prong frogger 
(Dan-Kar). For each spotting, three trials were carried 
out using the same microwell plate. This analysis was 
repeated at least twice for each yeast strain. 
 
Fluorescence Microscopy.  
Cells were visualized under a Nikon TE2000-U 
fluorescent microscope and images were acquired 
using the Metamorph 4.0 imaging software. About 750 
to 1000 cells were counted at several time-intervals 
depicted in the growth-rate analysis (18, 24, 36, and 48 
hours). For a qualitative analysis, three qualities were 
assessed and scored: plasma-membrane localization, 
cytoplasmic aggregates, and/or diffuse fluorescence. A 
ratio of the fluorescence patterns was created by 
characterizing about 750 cells according to their 
dominant phenotype: aggregate, diffuse, or membrane. 
Non-fluorescent cells were included in the total count to 
account for general expression levels.  
 
Results 
 
α-Synuclein Progressively Loses Membrane 
Localization and Forms Aggregates in kgd1∆ 
We evaluated the localization of α-synuclein in kgd1∆ 
against the BY4741 parent strain to understand its 
properties under conditions of mitochondrial 
dysfunction. At four time points, 18, 24, 36, and 48 
hours, fluorescence images were captured to assess 
the localization of α-synuclein-GFP. At 18 and 24 hours 
of induction, kgd1∆ and BY4741 yeast were 
phenotypically identical (phenotype not shown for 18 
hours; Figure 6 and 7). Yeast containing the parent 
pYES2.1 vector did not fluoresce (not shown). Cells 
with the GFP plasmid showed diffuse fluorescence in 
the cytoplasm, but not the vacuole. WT-α-synuclein 
expression showed intense plasma membrane 
localization with little or no diffuse fluorescence. A30P, 
A53T, and E46K exhibited a combination of 
cytoplasmically diffuse, aggregate, and plasma 
membrane localized fluorescence patterns.  
At 36 hours of expression, the kgd1∆ 
fluorescence phenotype slightly differed from its parent 
BY4741. A fraction of GFP-expressing cells showed 
aggregation by forming distinct foci (i.e. concentrated 
pixel intensity). The α-synuclein isoforms exhibited 
similar findings. Then, at 48 hours (Figure 6 and 7), this 
change was more prominent. In all kgd1∆ α-synuclein-
expressing cells, aggregates of α-synuclein were 
observed in higher numbers than BY4741 cells. 
Strikingly, WT, A53T, and E46K lost plasma membrane 
localization, whereupon cytoplasmic inclusions were 
found. These inclusions were in close proximity to the 
plasma membrane and seemingly attached at 48 hours. 
This result is noted by decreased plasma membrane 
fluorescence and increased inclusion presence near the 
cell wall. Surprisingly, inclusions found at 24 hours of 
expression were not near the plasma membrane, but 
were situated near the vacuole, however, not inside the 
vacuole (Figure 7A). 
The images captured over 48 hours were 
then quantified according to only three attributes: 
cytoplasmically diffuse, plasma membrane localized, 
and formation of foci or aggregates. In kgd1∆, GFP and 
all isoforms of α-synuclein showed a gradual 
progression to aggregate formation in a time-dependent 
manner. Aggregate formation was accompanied by loss 
of localization in each characteristic area. Thus, A30P-
expressing kgd1∆ cells lost both membrane and 
cytoplasmic localization as aggregates formed.   
 Approximately one out of seventy-five cells in 
both kgd1∆ and BY4741 exhibited complete auto-
fluorescence in each yeast strain. As the cells aged, 
this phenotype became more prevalent. Under DIC 
microscopy, these cells were smaller and displayed an 
irregular margin. Closer inspection revealed no 
vesicular trafficking or cytoplasmic activity, which is 
suggestive of cell death. Further analysis will have to be 
carried out to determine their exact fate. These cells 
were counted as diffuse. For example, in BY4741 WT-
α-synuclein-expressing cells, the quantified ratio shows 
some diffuse cells.  
  
 
 
Figure 6. α-Synuclein Localization in the Strain BY4741. A. Fluorescence Images. Images captured of S. cerevisiae BY4741 at 24 and 
48 hours of α-synuclein expression are shown. BY4741 cells show plasma membrane localization of α-synuclein-expressing cells at 24 and 
48 hours of induction as described in Sharma et. al. (2006). B. Quantification. The ratio of the three fluorescence patterns (i.e. diffuse, 
membrane, aggregate) was scored from 750 cells at 18, 24, 36, and 48 hours. WT, A53T, and E46K α-synuclein show plasma membrane 
localization. Both GFP and A30P predominantly show cytoplasmic localization. Minimal aggregates were observed under each condition. 
E46K, in general, displays less fluorescence.  
 
 
Figure 7. α-Synuclein Localization in the Strain kgd1∆. A. Fluorescence Images. Images captured of S. cerevisiae kgd1∆ at 24 and 48 
hours of α-synuclein expression are shown. In all samples, aggregates generally begin to appear at 24 hours, located in the cytoplasm. At 
48 hours, aggregates form near the membrane (red arrows). B. Quantification. The ratio of the three fluorescence patterns (i.e. diffuse, 
membrane, aggregate) was scored from 750 cells at 18, 24, 36, and 48 hours. GFP-expressing cells begin to exhibit aggregates at 36 
hours which is enhanced at 48 hours. Cytoplasmic localization steadily decreases over 48 hours. A30P-α-synuclein-expressing cells 
display a diffuse phenotype, which decreases in number as aggregates begin to form at 36 hours. WT, A53T, and E46K α-synuclein-
expressing cells all show membrane localization at 18 hours which also steadily declines as aggregates form at 24 hours.  
  
 
 
Figure 8. Growth Analysis and Expression of α-Synuclein in the Strain BY4741. A. Growth Curve. OD600 was assessed over a 48-
hour time course where toxicity was observed only in E46K-α-synuclein cells. Error bars represent standard deviation from three separate 
growth analyses. B. Serial Spotting. Growth was also assessed by serially diluting yeast cells fivefold in non-inducing (glucose) and 
inducing (galactose) media. E46K-expressing cells also displayed diminished growth under spotting. Both the growth curve and spotting 
analyses show that GFP has no affect on budding yeast growth.  
 
α-Synuclein is not Toxic in kgd1∆  
Next we examined toxicity of kgd1∆ by a using a 
spectroscopic (OD600nm) growth-rate analysis. This 
technique utilizes the density of cells to correlate 
degree of toxicity in actively dividing yeast. Error bars 
represent the standard deviation from three different 
trials. In the BY4741 parent strain, with the kgd1 gene, 
toxicity was observed with the E46K-α-synuclein 
isoform (Figure 8A).  
This result was also confirmed with the serial 
spotting growth analysis, where diminished growth was 
observed on inducing media (galactose) in E46K-α-
synuclein-expressing cells (Figure 8B). Glucose served 
as a loading control to ensure equal cell concentrations 
in each plasmid condition. Since equal growth was 
observed on the glucose media, this control allowed us 
to directly compare growth on galactose plates, which 
turn-on protein expression.  
However, in the kgd1∆ strain, no toxicity was observed 
in either growth analysis (Figure 9A and 9B). 
Interestingly, kgd1∆ cells had a faster doubling-time 
when compared to BY4741 at 12-hours of growth in log 
phase (Figure 8A and 9A).   
 
α-Synuclein Expression is Decreased in kgd1∆ 
To address the lack of toxicity, α-Synuclein expression 
was measured in kgd1∆.  At 24 hours of induction, all 
kgd1∆ strains showed significantly reduced expression 
when compared to BY4741 strains (Figure 9C). 
Interestingly, the fluorescence phenotype between both 
yeast strains showed roughly equivalent α-synuclein 
expression. Thus, the fluorescence phenotype cannot 
be used as an indicator of α-synuclein concentration.  
These results prompted induction of both 
strains for a 72-hour time-course to evaluate the 
change of α-synuclein expression over a longer period 
of time. I hypothesized that α-synuclein concentration 
would increase by 72-hours. Thus, lysates were 
prepared at three time points: 24, 48, and 72 hours for 
GFP and WT-GFP in kgd1∆, where BY4741 WT-GFP 
served as a control. Surprisingly, protein concentration 
in neither GFP nor WT-GFP expressing kgd1∆ cells 
changed (Figure 10A). 
Since GFP tagged WT-α-synuclein was used 
in figure 10A, I wanted to determine whether low 
expression was an α-synuclein specific effect or due to 
GFP. Thus, WT-α-synuclein (no GFP) was transformed 
into kgd1∆ to evaluate expression without GFP. 
Suprisingly, WT-α-synuclein (no GFP) in kgd1∆ 
displayed low expression when compared to BY4741 at 
24 hours of induction (Figure 10B). Additionally, LacZ, a 
harmless reporter gene, was also transformed into 
kgd1∆ to evaluate expression of “any” protein, in 
general. LacZ also showed diminished expression (data 
not shown). These data suggest that most foreign 
protein transformed into kgd1∆ would reveal decreased  
  
 
 
Figure 9. Growth Analysis and Expression of α-Synuclein in the Strain kgd1∆. A. Growth Curve. OD600 was assessed over a 48-hour 
time course with no observed toxicity. Error bars represent standard deviation from three separate growth analyses. B. Serial Spotting. 
Growth was also assessed by serially diluting yeast cells fivefold in non-inducing (glucose) and inducing (galactose) media. No toxicity 
observed. Both the growth curve and spotting analyses show that GFP has no affect on kgd1∆ budding yeast growth. C. Western Blot. For 
all samples, expression was induced for 24 hours and detected using an anti-α-synuclein monoclonal primary antibody (1:2000). The 
isogenic parent strain, BY4741, was used as a control to compare expression between BY4741 and kgd1∆. In kgd1∆, however, all α-
synuclein-expressing cells displayed decreased expression. Anti-phosphoglycerate kinase (PGK) primary monoclonal antibody (1:5000) 
was used as a loading control.  
 
expression compared to its isogenic parent strain, BY4741.  
In figure 10B, when we compare expression of each condition between BY4741 and kgd1∆, we see that kgd1∆ 
has overall decreased expression. However, this does not tell us whether GFP or α-synuclein alone is having an effect on 
expression. To determine this, we must look at expression within each strain and not between strains. WT-α-synuclein (no 
GFP) expressed in BY4741 and kgd1∆ shows enhanced expression when compared to WT-α-synuclein-GFP in both 
strains, respectively. Thus, GFP is causing decreased expression in both strains.     
 
α-Synuclein Localization in glo4∆ does not Change 
In another mitochondrial mutant, glo4∆, α-synuclein localization was remarkably similar to BY4741 (Figure 5 and 11). The 
quantification of the glo4∆ phenotype reveals fluorescence patterns that are nearly identical to the isogenic parent strain, 
BY4741.  The only difference is that E46K-α-synuclein expressing glo4∆ cells have a higher number of cells that fluoresce 
when compared to BY4741 cells. Again, the number of cells that fluoresce is not indicative of protein expression.  
 
α-Synuclein is not Toxic in glo4∆  
We next evaluated whether or not α-synuclein was toxic to the strain glo4∆. No toxicity was observed in glo4∆ from either 
spectroscopic growth-rate analysis (Figure 12A) or serial spotting (Figure 12B). Some variation was observed in the first 
12 hours of growth, which is within the standard deviation of three trials. Compared to kgd1∆, the doubling-time of glo4∆ 
is not as fast. Since α-synuclein was not found to be toxic in glo4∆ or kgd1∆, plus kgd1∆ exhibited low expression, we 
expected to observe diminished expression in glo4∆, as well.  
 
α-Synuclein Expression in glo4∆ is Lower than BY4741, but not kgd1∆ 
\We measured the expression of α-synuclein to determine if low expression was correlated with low toxicity. At 24 hours of 
induction, BY4741 was again noted to have decreased E46K-α-synuclein expression (Figure 12C). All isoforms of α-
synuclein and GFP displayed decreased expression in glo4∆ when compared to BY4741, but not nearly as severe as 
kgd1∆. No further expression analysis was completed as done in kgd1∆.  
   
 
  
 
 
 
Figure 10. Time-Course and Non-GFP Tagged WT-α-Synuclein Expression in BY4741 and kgd1∆ Yeast Strains. A. 72-Hour Time 
Course Western Blot. In GFP and WT-α-Synuclein-expressing kgd1∆ cells, expression did not change over a 72-hour period. B. Effect of 
GFP on kgd1∆. Compared to BY4741, all foreign proteins in kgd1∆ had diminished expression. Additionally, non-GFP tagged WT-α-
Synuclein in BY4741 exhibited increased expression and variable banding when compared to WT-α-Synuclein-GFP. Anti-phosphoglycerate 
kinase (PGK) primary monoclonal antibody (1:5000) was used as a loading control in both experiments.  
 
 
 
Figure 11. α-Synuclein Localization in the Strain glo4∆. A. Fluorescence Images. Images captured of S. cerevisiae glo4∆ at 24 and 48 
hours of α-synuclein expression are shown. glo4∆ cells show plasma membrane localization of α-synuclein-expressing cells at 24 and 48 
hours of induction. 
 
 
  
 
B. Quantification. The ratio of the three fluorescence patterns (i.e. diffuse, membrane, aggregate) was scored from 750 cells at 24 and 48 
hours. WT, A53T, and E46K α-synuclein show plasma membrane localization. A30P-α-synuclein displays a mix of plasma membrane and 
cytoplasmic localization. GFP predominantly shows cytoplasmic localization. Minimal aggregates were observed under each condition.  
 
 
Figure 12. Growth Analysis and Expression of α-Synuclein in the Strain glo4∆. A. Growth Curve. OD600 was assessed over a 48-
hour time course with no observed toxicity. Error bars represent standard deviation from three separate growth analyses. B. Serial Spotting. 
Growth was also assessed by serially diluting yeast cells fivefold in non-inducing (glucose) and inducing (galactose) media. No toxicity 
observed. Both the growth curve and spotting analyses show that GFP has no affect on glo4∆ budding yeast growth. C. Western Blot. For 
all samples, expression was induced for 24 hours and detected using an anti-V5 monoclonal primary antibody (1:5000). The isogenic 
parent strain, BY4741, was used as a control to compare expression between BY4741 and glo4∆.  In BY4741, decreased E46K-α-
synuclein expression was observed again. In glo4∆, however, all α-synuclein-expressing cells displayed decreased expression. GFP 
expression was also in  decreased in glo4∆ comparison to BY4741. Anti-phosphoglycerate kinase (PGK) primary monoclonal antibody 
(1:5000) was used as a loading control.  
  
Thus, lowered expression was found to be correlated 
with low toxicity. Seemingly, lower expression in kgd1∆ 
compared to glo4∆, allowed kgd1∆ to grow slightly 
faster despite the presence of aggregates.  
 
Discussion 
  
The complex interplay between oxidative stress and α-
synuclein folding is becoming clearer as we evaluate 
the role of the mitochondria in Parkinson’ disease. 
Here, I evaluated two yeast strains with different 
mitochondrial mutations, kgd1∆ and glo4∆. Both gene 
deletions affected α-synuclein aggregation and toxicity 
in different manners.  
Toxicity was not observed in both knockout 
strains even after the addition of α-synuclein. Both 
knockout strains exhibited decreased expression when 
compared to their isogenic parent strain, BY4741. 
Finally, only kgd1∆ displayed time-dependent 
aggregate formation in all GFP-related proteins 
combined with the least expression observed.  
  
Does Decreased α-Synuclein Expression Diminish 
Toxicity? 
One common theme of no toxicity in kgd1∆ and glo4∆ 
cells is the lack of moderate α-synuclein to challenge 
the cells. Lowered expression may be a protective 
mechanism for the cell. Since toxicity was not observed 
in these two cases, we can suggest that toxicity is 
related to levels of α-synuclein.  
Interestingly, toxicity was observed in low-
expressing E46K-α-synuclein BY4741 cells (Figure 7). 
This is contradictory to the result seen in both kgd1∆ 
and glo4∆ cells (Figure 9 and 12). Here we could 
suggest that E46K is more toxic than all other α-
synuclein isoforms. Yet, why don’t we see toxicity in 
E46K-expressing kgd1∆ and glo4∆ cells?  
 Despite low α-synuclein expression, only 
kgd1∆ displays the formation of aggregates. 
Aggregates may be protective in kgd1∆ cells, thus 
E46K would be inactive to cause harm to the cell. This 
may be due to ROS generation by inhibition of 
mitochondrial complex I (Figure 4). Enhanced ROS 
content may induce general protein misfolding in the 
cell by disrupting cellular machinery necessary for 
proper protein folding.  
However, glo4∆ does not have aggregates or 
toxicity. It is important to note that aggregates are not a 
requirement for toxicity. Also, lack of aggregates does 
not imply toxicity (Conway et. al., 1998). What 
compensatory mechanism does glo4∆ have to reduce 
E46K-based toxicity? The glo4∆ strain lacks a pivotal 
antioxidant, but does not generate ROS as a result. 
Since ROS formation is not induced in glo4∆, maybe 
the cell overcompensated for the lack of antioxidants by 
expressing other proteins to clear excess ROS. Thus, 
the cell may have not been in a toxic state from the very 
beginning. Also, since we did not challenge the cells 
with any oxidants, we do not know the threshold at 
which protein aggregation would commence within 
glo4∆ cells.  
Additionally, in previous studies within our 
lab, no aggregates were observed in compromised cells 
lacking manganese superoxide dismutase but with α-
synuclein and hydrogen peroxide (Sharma et. al., 
2006). Thus, toxicity was observed without visible 
protein aggregation. More research must be done to 
uncover the toxic element within these cells. 
 
 
Are Aggregates Protective? 
Intense debate in the field of neurodegenerative 
diseases strives to understand if aggregates are toxic 
or protective. Since α-synuclein-rich Lewy bodies are 
correlated with Parkinson’s disease, much investigation 
has gone into understanding why and how α-synuclein 
aggregates (Spillantini et. al., 1998). In kgd1∆, toxicity 
is absent but aggregates are not. Thus, the combination 
with low expression and agg`regation may be a 
protective mechanism for the cell. Additionally, since 
aggregates do not form until 36 to 48 hours of 
expression, we cannot determine whether or not they 
are toxic since growth reached a plateau phase at that 
time.  
Emerging evidence suggests that circular 
trimeric protofibrils are the toxic agent in NDD (Lashuel 
et. al.,2002). Through a pore-like mechanism they can 
permeabilize a membrane or vesicle which diminishes 
the integrity of the cell. Protofibrils are the intermediate 
of fibrils and are thought to contribute to cytotoxicity 
more than larger aggregates. In our investigation, 
toxicity is observed only in the E46K-expressing 
BY4741 cells. Since aggregates are not readily found 
under this condition, we can suggest that this model 
supports the protofibril hypothesis due to membrane 
localization in fluorescent cells. Also, within our fission 
yeast model (Chapter 2), toxicity is also absent in cells 
with abundant aggregates. 
 
Where do α-Synuclein Aggregates Localize? 
It is important to note that aggregation observed in 
kgd1∆ begins within the cells’ interior at 24 hours and 
moves to the membrane at 48 hours. We are not sure 
whether or not the membrane aggregates observed at 
48 hours are formed from loss of membrane localization 
or vesicular transport to the membrane (Caughey et. 
al., 2003). One clue points to vesicular transport. Since 
GFP also forms these characteristic aggregates, 
plasma membrane localization is not necessary for 
membrane-bound aggregate formation. The same 
argument applies for A30P-α-synuclein. Yet, this does 
not discount the idea that retrograde vesicular transport 
from the membrane may create these distinct 
aggregates. Both pathways may be operating.  
 
Does Genetic Diversity in the Mitochondria Change α-
Synuclein’s Properties? 
Our laboratory’s investigation of three mitochondrial 
mutants have regulated α-synuclein’s aggregation and 
toxicity in three completely different ways. In summary, 
kgd1∆ cells showed aggregation with no toxicity; glo4∆ 
cells displayed no aggregation with no toxicity; and 
sod2∆ cells (lacking manganese superoxide dismutase) 
exhibited toxicity without aggregation. This research 
immediately points to the complexity of mitochondrial 
dysfunction in Parkinson’s disease. Slight differences 
within any of these genes will regulate α-synuclein 
properties in very different ways. Thus, aging and the 
accumulation of oxidants will also be different. Yet, one 
conclusion can be made: α-synuclein interacts with the 
mitochondria in PD pathogenesis.  
 
 
 
 
 
 
 
 
  
Construct Expression Vector Strain 
A76E-α-Synuclein-
GFP 
pYES2.1 BY4741 
A76E-α-Synuclein-
GFP 
pNMT1 TCP1 
 
Table 2. List of Transformed Budding and Fission Yeast Strains for Chapter 2 
 
Chapter 2: The A76E α-Synuclein Mutation Reduces 
Aggregation in Fission Yeast 
 
Materials and Methods 
 
Please refer to Chapter 1: Mitochondrial Mutants for 
complete experimental procedures in S. cerevisiae. 
Methods adapted from Brandis et. al. (2006).  
 
S. cerevisiae expression vectors.  
A76E mutant α-synuclein was created from WT-α-
synuclein using GeneTailorTM Site-Directed  
Mutagenesis in a pYES2.1/TOPO expression vector 
(Table 2 and Figure 13 and 14; Invitrogen).   
 
S. pombe expression vectors.  
A76E mutant α-synuclein was created from WT-α-
synuclein using GeneTailorTM Site-Directed 
Mutagenesis in a pNMT-1 TOPO-TA expression vector 
(Table 2 and Figure 13 and 14; Invitrogen).   
 
Yeast Strains. 
BY4741 (MATa his3∆1 leu2∆0 met15∆0 ura3∆0) was 
purchased from Open Biosystems (Huntsville, AL). 
TCP1 (h- leu1-32; Invitrogen) 
 
Yeast Transformation.  
S. cerevisiae and S. pombe  strains were transformed 
with the pYES2.1 and pNMT-1 vectors, respectively, 
using the lithium-acetate transformation method (Alfa 
et. al., 1993). 
 
Fluorescence Microscopy.  
S. pombe cells were grown overnight at 30 °C in 
Edinburgh Minimal Medium (EMM; Invitrogen) 
containing thiamine (10 µM; to repress α-synuclein 
expression).  After 24 hours, cells were pelleted at 
1500xg for 5 min, washed twice in 10 mL dH20, 
resuspended in 10 mL EMM without thiamine, of which 
125 µl of cells were used to inoculate 25 mL EMM 
without thiamine (to express α-synuclein).  Cells were 
viewed using a Nikon TE-2000U fluorescence 
microscope at 1000X magnification. Images were 
deconvoluted using the MetaMorph version 4.2 
software. To quantify α-synuclein aggregates in Figure 
13, cells were first viewed under differential interference 
contrast (DIC) microscopy and total cell count in the 
field was determined. The same cells in the field were 
then viewed for GFP fluorescence. The number of cells 
in the field containing 1, 2, or 3+ aggregates or a diffuse 
phenotype was determined. At least 750 cells were 
evaluated for each condition. Aggregates were scored 
as ratio of total cells in the field that expressed 1, 2, and 
3+ aggregates, or a diffuse phenotype. 
 
Protein Expression.  
Lysates of S. pombe expressing α-synuclein, protein 
electrophoresis, and Western blotting, were performed 
as reported for S. cerevisiae in Sharma, 2004. The 
monoclonal anti-V5 antibody-AP (Invitrogen; 1:5000 
dilution) was used for protein detection. Anti-β-actin 
primary monoclonal antibody (1:2500) was used as a 
loading control for S. pombe only.  
 
Growth Curve.  
Transformed cells were grown in 10 mL EMM + 
thiamine overnight at 30 °C, 200 rpm. Cells were 
harvested at 1500 x g for 5 min at 4°C, washed twice in 
5 mL dH20, re-suspended in 5 mL dH20 and counted. 
Flasks with 25 mL EMM + thiamine or EMM – thiamine, 
were each inoculated to 2.0x106 cells/mL density. At 0, 
3, 6, 12, 18, 24, and 36 hours, OD600 absorbance of 
one mL cell culture (in duplicate) was measured using a 
Hitachi U-2000 Spectrophotometer. Averaged 
absorbance readings were plotted against time points.  
 
Serial Spotting.  
For spotting, transformed cells were grown to mid-log 
phase in EMM + thiamine, normalized to equal 
densities (2x107 cells/ml), serially diluted (five-fold) into 
96-well microtiter plates and spotted on EMM + 
thiamine or EMM - thiamine plates using a 48-prong 
frogger (Dan-Kar) or manual pipeting.  Images were 
photographed after two days of growth. 
 
Results 
 
A76E-α-Synuclein Localizes to the Membrane More 
Slowly 
We first asked if the A76E-α-synuclein mutation would 
change membrane binding affinity in budding yeast. At 
24 hours of expression, A76E-α-synuclein displayed a 
diffuse phenotype mixed with plasma membrane 
localization in BY4741 (Figure 15A and 15B), similar to 
A30P-α-synuclein (Figure 6). At 48 hours, plasma 
membrane localization became the dominant 
phenotype with little to no cytoplasmic localization. At 
the same time point, A30P-α-synuclein remains in the 
cytosol (Figure 6). Thus, the A76E-α-synuclein mutation 
is distinctly different from A30P-α-synuclein. WT-α-
synuclein did not produce a diffuse phenotype as 
observed in A76E-α-synuclein-expressing cells at 24 
hours. Yet, at 48 hours, A76E-α-synuclein resembled 
the WT-α-synuclein phenotype. 
 
A76E-α-Synuclein Reduces the Rate of Aggregation 
Next, we examined if A76E-α-synuclein reduces its rate 
of aggregation. In fission yeast, a similar phenomenon 
occurred. A mixed diffuse and aggregate phenotype 
was observed in A76E-α-synuclein-expressing cells at 
24 hours (Figure 15C and 15D). By 48 hours, however, 
A76E-α-synuclein translocated from the cytoplasm to 
the plasma membrane. Yet, the total number of 
fluorescing cells decreased at 48 hours (Figure 15 D). 
As expected, WT-α-synuclein did not produce a diffuse 
phenotype as observed in A76E-α-synuclein-
expressing cells at 24 hours. At 48 hours, WT-α-
synuclein appeared distinctly different from A76E-α-
synuclein.  
 
 
  
 
 
 
 
Figure 13. Diagrammatic Flowchart for Mutagenesis. Adapted from GeneTailorTM Site-Directed Mutagenesis (Invitrogen). For each 
expression vector, pNMT1 and pYES2, the A76E mutation was created in α-synuclein. Thus, each vector underwent a separate 
mutagenesis reaction. Each vector was first methylated with DNA methylase for 1 hour at 37 °C. The methylated DNA was then used for 
PCR amplification with two overlapping primers, one of which contained the desired mutation. This reaction yielded mutated DNA along 
with the methylated template DNA. The products were transformed into E. coli which circularized the linear DNA and digested the 
methylated template. The plasmid was isolated once again and sequenced at The University of Chicago (Chicago, IL).  
 
 
 
 
 
  
 
 
Figure 14. A76E-α-Synuclein-GFP Site-Directed Mutagenesis. The A76E-α-Synuclein-GFP mutation was created using the 
GeneTailorTM Site-Directed Mutagenesis System (Invitrogen). A. Primer Design. The forward mutagenesis primer was designed to change 
one nucleotide, within the 76th codon of α-synuclein-GFP (C-terminus), from Cytosine (C) to Adenine (A). The mutation of one nucleotide 
from C to A changes the 76th codon to glutamic acid (E) instead of alanine (A). Oligonucleotides were ordered from Operon (Qiagen). B. 
Plasmid DNA Isolation. DNA plasmid vectors, pYES2 (lane 2) and pNMT-1 (lane 3) containing WT-α-synuclein fused with GFP at the 
Carboxy-terminal domain, were isolated from E. coli stored at -80 °C using the QIAprep Spin Miniprep Kit (Qiagen). 1: λ/HIND III Ladder 
(base pairs), 2: pYES2 WT-α-Synuclein-GFP, 3: pNMT-1 WT-α-Synuclein-GFP. C. Mutagenesis Reaction. Polymerase Chain Reaction 
(PCR) reagents and primers containing the target mutation were combined with the a methylated target plasmid for the mutagenesis. Taq 
polymerase allows the reaction to proceed. Reactions lacking Taq served as negative controls. Mutagenesis products for the pNMT-1 and 
pYES2 vectors are seen in lane 4 and 6, respectively. 1: AmpliSize Ladder (base pairs), 2: Positive Control pYES2 Plasmid, 3: –Taq pNMT-
1 WT-α-Syn-GFP, 4: +Taq pNMT-1 WT-α-Syn-GFP, 5: –Taq pYES2 WT-α-Syn-GFP, 6: +Taq pYES2 WT-α-Syn-GFP. D. Transformed 
DH5α-T1 E. coli with Mutated Vectors. All plates were made with ampicillin (50 µg/mL) and X-gal (100 µg/mL) to select for non-transformed 
E. coli and screen blue/white colonies, respectively (i.e. white indicates a successful transformation and functional lacZ gene).  Positive 
control, plate 1, was transformed with a pUC19 vector containing an ampicillin resistance gene, which was supplied by the mutagenesis kit 
(Qiagen). The negative control, plate 2, was not transformed with the pUC19, thus was not able to grow on the media. Plate 3 and 4 served 
as methylation controls where S-adenosylmethionine (SAM) enhances DNA methylation. Plate 3 shows that enhanced methylation 
increases the selectivity of colonies. Plate 5 and 6 are colonies of E. coli contaning vectors with the human cDNA A76E-α-synuclein-GFP 
gene. Positive transformants were screened by bacterial whole cell PCR. Plasmid vectors were purified using a Qiagen mini-prep kit and 
the respective DNA sequences were confirmed at The University of Chicago Cancer Research Center DNA Sequencing Facility (Chicago, 
IL). 1: Positive Control, 2: Negative Control, 3: Methylation Control –SAM, 4: Methylation Control –SAM, 5: pNMT-1 A76E-α-Synuclein-
GFP, 6: pYES2 A76E-α-Synuclein-GFP. 
 
 
 
  
 
 
Figure 15. A76E-α-Synuclein Localization in BY4741 and TCP1 Yeast Strains. A & C. Fluorescence Images. Images captured of S. 
cerevisiae BY4741 and S. pombe TCP1 at 24 and 48 hours of α-synuclein expression are shown. B & D. Quantification. The ratio of 
different fluorescence patterns was scored from 750 cells at 24 and 48 hours. At 24 hours in BY4741, A76E-α-synuclein displayed 
cytoplasmic localization which moved to the membrane by 48 hours. At 24 hours in TCP1, A76E-α-synuclein exhibited a diffuse phenotype, 
also seen in A30P-α-synuclein-expressing S. pombe fission yeast (Brandis et. al., 2006). At 48 hours, this phenotype was less pronounced.  
 
Figure 16. Growth Analysis and Expression of A76E-α-Synuclein in the Strains BY4741 and TCP1. A. Growth Curve. OD600 was 
assessed over a 48-hour time course with no observed toxicity in either BY4741 or TCP1. Both non-inducing (glucose and +thiamine) and 
inducing (galactose and -thiamine) growth conditions are shown with A76E-α-synuclein expression. Error bars represent standard deviation 
from three separate growth analyses.  
  
 
 
B. Serial Spotting. Growth was also assessed by serially diluting yeast cells fivefold in non-inducing (glucose and +thiamine) and inducing 
(galactose and -thiamine) media. No toxicity observed. C. Western Blot. For all samples, expression was induced for 24 and 48 hours and 
detected using an anti-V5 monoclonal primary antibody (1:5000). In BY4741, A76E-α-synuclein expression is decreased only at 24 hours. 
In TCP1, WT and A76E α-synuclein expression is the same. Anti-phosphoglycerate kinase (PGK) primary monoclonal antibody (1:5000) 
was used as a loading control for budding yeast, S. cerevisiae BY4741. Anti-β-actin primary monoclonal antibody (1:2500) was used as a 
loading control for fission yeast, S. pombe TCP1.  
 
No Toxicity Found in A76E-α-Synuclein-Expressing 
Yeasts 
We next evaluated the growth of fission and budding 
yeast combined with A76E-α-synuclein. Growth 
analysis was done by expressing α-synuclein with EMM 
–Thiamine (pNMT vector is thiamine repressible). Thus, 
EMM +Thiamine represses the promoter and prevents 
expression, thereby serving as a loading control. 
Similarly, induction refers to the onset of protein 
expression. Thus, the induction of α-synuclein is not 
toxic to budding and fission yeast (Figure 16A and 
16B).  
 
Discussion 
 
Our studies with A76E-α-synuclein have shown that a 
single amino acid substitution can change the 
aggregation kinetics of a pathogenic protein. Instead of 
creating A76E-α-synuclein and testing its properties in 
vitro, we utilized an in vivo approach in yeast to mimic 
the cellular stresses experienced by aging neurons.  
  In fission yeast, a full aggregation phenotype 
without diffuse fluorescence was delayed to 48 hours of 
expression (Figure 15). Thus, the mutation changed the 
shape of α-synuclein enough to prevent self-assembly 
for about 24 hours when compared to WT-α-synuclein 
(Figure 15A and 15B). In budding yeast, A76E-α-
synuclein delayed full membrane localization for a 
similar 24 hour period. 
 
How does the A76E Mutation Alter α-Synuclein 
Localization? 
As described by Chiti and colleagues (2003), 
hydrophobicity, propensity of secondary structure 
conversion from α-helix to β-sheet, and charge allow us 
to mathematically characterize the aggregation rates of 
proteins and peptides. The A76E-α-synuclein mutation 
converted the 76th amino acid codon from methyl to 
glutamic acid which gave it an overall positive charge 
(Figure 17). The energy needed for it to form a β-sheet, 
pathogenic shape found in prions (Caughey et. al., 
2003), increased by a magnitude of ~1.5. Thus, the 
dominant secondary shape would be α-helical. Finally, 
the mutation induced a threefold decrease in 
hydrophobicity. All of these factors combined account 
for a protein engineered for cytoplasmic solubility.  
 
Is Decreased α-Synuclein Expression a Protective 
Mechanism?  
Less expression in budding yeast at 24 hours coupled 
with cytoplasmic localization may be due to time and 
concentration-dependent assembly of proteins. 
Because at 48 hours of induction, A76E-α-synuclein 
begins to localize to the membrane from the cytoplasm 
and expression is also enhanced. Thus, over time, 
expression increases and so does assembly of α-
synuclein to the membrane. 
Additionally, toxicity was not observed at this 
time point. Decreased expression and lack of toxicity is  
  
 
 
Figure 17. How Does A76E-α-Synuclein Delay Aggregation 
in Fission Yeast? Mutation Induces a Shape Change. The 
A76E mutation in α-synuclein must bring on a shape change, 
thereby postponing self-assembly. At a low pH, glutamic acid is 
negatively charged, which may aid in aggregate repulsion. 
Increased hydrophilicity, α-helix to β-sheet conversion,  may 
also play a role as described in Chiti et. al. (2003). 
 
consistent with out budding yeast knock-out models 
(Chapter 1).  
 
What is the Toxic Species? 
Lack of toxicity in the diffuse and aggregate states 
places a dichotomy between the protofibril and 
aggregate theory for toxicity. Since both phenotypes 
exist without toxicity, α-synuclein could be harmless to 
fission yeast. The phenotypes investigated here are 
similar to those found A30P-α-synuclein. Yet, A30P-α-
synuclein does not aggregate in fission yeast to the 
degree of A76E-α-synuclein. However, investigations 
by Willingham et. al. (2003) have revealed 86 genes 
that protect against α-synuclein toxicity in budding 
yeast. A similar screen in fission yeast may reveal 
relevant genes that rescue PD pathogenesis (Brandis 
2006). Thus, budding yeast may be adept to handling a 
toxic load of proteins due to its own genetic makeup.  
Importantly, fission and budding yeast are 
separated by about 400 million years from their earliest 
evolutionary ancestor (Sipiczki et. al., 2000). The 
different phylogenies of both yeasts would undoubtedly 
contribute to a different genome and, thus, different 
handling of foreign proteins. As of now, we have not 
been able to induce toxicity within α-synuclein-
expressing fission yeast. We believe that α-synuclein 
woud be toxic when combined with an oxidizing 
substrate, such as hydrogen peroxide. The threshold 
for toxicity may then be reached.  
 A second possibility is a non-toxic protofibril 
model. There is no current scientific support for this 
theory, but it is a hypothesis that has not been refuted. 
Since there is lack of toxicity in both aggregate and 
cytoplasmic phenotypes in fission yeast, α-synuclein 
could be protective in both protofibrillar and fibrillar 
forms.  
However, the third hypothesis could describe α-
synuclein as a completely harmless protein in fission 
yeast. This may be due to the differences in membrane 
composition between budding and fission yeast. If the 
membrane is slightly different in composition of 
phospholipids and glycolipids, α-synuclein’s membrane 
binding properties may change (Davidson et. al., 1998). 
 
Conclusions 
 
Using budding and fission yeast models of Parkinson’s  
disease, we have inexpensively recreated a genetically 
flexible neuron to study protein misfolding and related 
toxicity. To study why dopaminergic degeneration is so 
specific, yeast serve as a good starting point to screen 
genes responsible for enhancing α-synuclein 
aggregation in response to oxidative stress. Although 
this system does not include compounds and 
substrates like dopamine or neuromelanin, we can 
genetically induce their effects, reactive oxygen species 
generation.  
 Yeast have conserved protein trafficking 
machinery and mitochondrial proteins that share 
similarities with humans, which allow us to study the 
effects of mitochondrial dysfunction on α-synuclein 
toxicity.  
 Evaluation of the two budding yeast 
mitochondrial mutants, kgd1∆ and glo4∆, have shown 
us that α-synuclein isoforms and the mitochondria 
interact in various ways to produce PD in different 
ways. Studies with A76E-α-synuclein have elucidated 
the three keys to aggregation kinetics: charge, 
secondary structure, and hydrophobicity. 
 
Limitations   
Determining the phenotype of a fluorescence image is a 
subjective process that can be performed at different 
capacities at different times. For example, it is usually 
difficult to distinguish between an auto-fluorescing cell 
and a cell exhibiting a diffuse phenotype. The charged-
coupled device on the camera finds the brightest pixel 
on the field of view and assigns that the highest 
numerical value for light intensity. So, if two objects 
were in the field of view and one was more brightly 
fluorescing, then the weakly fluorescing cell would be 
diminished even more. Thus, high variability in 
fluorescence within the sample will bring difficulty when 
assessing the fluorescence patterns.   
 Additionally, the limit of experiments available 
to analyze α-synuclein aggregates in kgd1∆. Since the 
aggregates seen in kgd1∆ are novel due to their 
membrane-bound nature, it would be interesting to 
investigate the lipid content of these aggregates. More 
sophisticated techniques in molecular biology may be 
able to unravel the contents of these protein inclusions.  
 
Future Directions 
Four goals should be pursued in the future. First, it 
would be appropriate to evaluate the removal of the 
other citric acid cycle enzymes and test the effects of α-
synuclein misfolding and toxicity. Second, the level of 
oxidative stress should be evaluated by measuring 
oxidatively modified proteins or using a DHR 123, a 
fluorescent detector of reactive oxygen species. Third, 
the A76E-α-synuclein experiments need to be repeated 
in order to statistically evaluate the novel localization 
properties found with this protein. Finally, toxicity should 
be defined by characterizing cell growth, cell death, and 
apoptosis with a chemical agent.  
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